1392809-08-3
1392809-08-3
Chemical Structure
MRL-871
- CAS No.: 1392809-08-3
- Formula:C22H12ClF3N2O3
- Molecular Weight:444.79
IUPAC Name: 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid
InChIKey: DANLZOIRUUHIIX-UHFFFAOYSA-N
SMILES: O=C(C1=CC=C(C=C1)C2=NN(C3=C2C=CC=C3)C(C4=C(C=CC=C4Cl)C(F)(F)F)=O)O
Biological Activity: MRL-871 (compound 3) is a potent and allosteric retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists with an IC50 of 12.7 nM. MRL-871 has a distinct isoxazole chemotype and effectively reduces IL-17a mRNA production in EL4 cells[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MRL-871 | 99.11% | MRL-871 (compound 3) is a potent and allosteric retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists with an IC50 of 12.7 nM. MRL-871 has a distinct isoxazole chemotype and effectively reduces IL-17a mRNA production in EL4 cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
LXR-623 | 99.95% | LXR-623 is a brain-penetrant partial LXRα and full LXRβ agonist, with IC50s of 24 nM and 179 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
YD-3 | YD-3 is a platelet activation inhibitor. YD-3 inhibits Thrombine-induced rabbit platelets aggregation (IC50: 28.3 μM) and phosphoinositol production. In addition, YD-3 also inhibits Trypsin-induced platelet aggregation in human and rabbit with the IC50 of 38.1 μM and 5.7 μM, respectively, but does not affect the proteolytic activity of trypsin. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TrkA-IN-3 | 98.01% | TrkA-IN-3 is a potent, subselective and allosteric TrkA inhibitor, with an IC50 of 22.4 nM. TrkA-IN-3 shows more than 8000-fold selectivity for TrkA over TrkB and TrkC. TrkA-IN-3 can be used for the research of pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Antihypertensive agent 2 | Antihypertensive agent 2 (Compound 4g) is an antihypertensive agent. Antihypertensive agent 2 has effective antagonistic activities against angiotensin II receptor 1. Antihypertensive agent 2 reduces the blood pressure with equal or more potency compared to Losartan (HY-17512). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BHD | BHD is an effective, orally active and reversible contraceptive agent. BHD induces the apoptosis of spermatogenic cells rapidly and disruptes the blood-testis barrier effectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HBV-IN-43 | HBV-IN-43 (compound 5832) is a potent inhibitor of HBV. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
EP4 receptor antagonist 7 | 99.9% | EP4 receptor antagonist 7 (Compound 14) is an antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4 with an IC50 value of 1.1 nM. EP4 receptor antagonist 7 inhibits PGE2-induced β-arrestin recruitment in HEK293 cells with an IC50 value of 0.9 nM. EP4 receptor antagonist 7 decreases PGE2-induced expression of mRNA encoding IL-4, macrophage mannose receptor 1 (Mrc1), chitinase-like protein 3 (Chil3), chemokine (C-X-C) motif ligand 1 (Cxcl1), triggering receptor expressed on myeloid cells 2 (Trem2), and arginase-1 (Arg1), in RAW 264.7 macrophages. EP4 receptor antagonist 7 combined with an anti-PD-1 antibody inhibits tumor growth and increases infiltration of CD8+ T cells into tumors in a CT26 murine colon cancer model. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HDAC6-IN-60 | HDAC6-IN-60 (Compound 12) is an orally active and selective HDAC6 inhibitor. HDAC6-IN-60 exerts effects on tumor cell proliferation by inhibiting the enzymatic activity of HDAC6 and regulating pathways related to protein homeostasis. HDAC6-IN-60 is promising for research of HDAC6- related cancers. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HDAC6-IN-66 | HDAC6-IN-66 is a potent and selective histone deacetylase (HDAC) 6 inhibitor with an IC50 of 1.8 nM. HDAC6-IN-66 induces α-tubulin acetylation over histone H3. HDAC6-IN-66 can be used for the research of cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GNE-0946 | 98.11% | GNE-0946 is a potent and selective RORγ( RORc) agonist with an EC50 value of 4 nM for HEK-293 cell. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
